Activation of adenosine A1 receptor attenuates tumor necrosis factor-α induced hypertrophy of cardiomyocytes

Biomedicine and Pharmacotherapy

Volumn 65, Issue 7, 2011, Pages 491-495

  Liao, Yulin ^a   Lin, Li ^a   Lu, Di ^a   Fu, Yujun ^a   Bin, Jianping ^a   Xu, Dingli ^a   Kitakaze, Masafumi ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Adenosine; Hypertrophy; Tumor necrosis factor

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 6 N CYCLOPENTYLADENOSINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; LEUCINE; MESSENGER RNA; TRITIUM; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL;

ADAM PROTEINS; ADENOSINE; ADENOSINE A1 RECEPTOR AGONISTS; ANIMALS; ANIMALS, NEWBORN; AORTA; AORTIC VALVE STENOSIS; CARDIOMYOPATHY, HYPERTROPHIC; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LIGATION; LUNG; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; ORGAN SIZE; RATS; RECEPTOR, ADENOSINE A1; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80555131042     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.06.008     Document Type: Article

References (32)

1. Higuchi Y., Otsu K., Nishida K., et al. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 2002, 34:233-240.
2. van Empel V.P., De Windt L.J. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 2004, 63:487-499.
3. Stamm C., Friehs I., Cowan D.B., et al. Inhibition of tumor necrosis factor-alpha improves postischemic recovery of hypertrophied hearts. Circulation 2001, 104:I350-I1355.
4. Smith R.M., McCarthy J., Sack M.N. TNF alpha is required for hypoxia-mediated right ventricular hypertrophy. Mol Cell Biochem 2001, 219:139-143.
5. Stetson S.J., Perez-Verdia A., Mazur W., et al. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha. Circulation 2001, 104:676-681.
6. Wang X., Oka T., Chow F.L., et al. Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009, 54:575-582.
7. Takei Y., Di Tullio M.R., Homma S., et al. Soluble tumor necrosis factor receptor 1 level is associated with left ventricular hypertrophy: the northern Manhattan study. Am J Hypertens 2009, 22:763-769.
8. Sriramula S., Haque M., Majid D.S., Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008, 51:1345-1351.
9. Yokoyama T., Nakano M., Bednarczyk J.L., McIntyre B.W., Entman M., Mann D.L. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997, 95:1247-1252.
10. Meyer TE, Chung ES, Perlini S, et al. Antiadrenergic effects of adenosine in pressure overload hypertrophy. Hypertension 2001;37:862-8.
11. Pang T., Gan X.T., Freeman D.J., Cook M.A., Karmazyn M. Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2010, 298:H545-H553.
12. Holycross B.J., Li P., Jackson E.K. Adenosine-angiotensin II interactions, Part II. The role of adenosine in regulating angiotensin II-induced changes in heart rate and aldosterone release. J Pharmacol Exp Ther 1989, 250:442-453.
13. El-Ani D., Zimlichman R., Mashiach Y., Shainberg A. Adenosine and TNF-alpha exert similar inotropic effect on heart cultures, suggesting a cardioprotective mechanism against hypoxia. Life Sci 2007, 81:803-813.
14. Funakoshi H., Zacharia L.C., Tang Z., et al. A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation 2007, 115:2307-2315.
15. Villarreal F., Epperson S.A., Ramirez-Sanchez I., Yamazaki K.G., Brunton L.L. Regulation of cardiac fibroblast collagen synthesis by adenosine: roles for Epac and PI3K. Am J Physiol Cell Physiol 2009, 296:C1178-C1184.
16. Dubey R.K., Gillespie D.G., Mi Z., Jackson E.K. Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension 2001, 37:1095-1100.
17. Headrick J.P., Peart J.N., Reichelt M.E., Haseler L.J. Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochim Biophys Acta 2010, 1808:1413-1428.
18. Funaya H., Kitakaze M., Node K., Minamino T., Komamura K., Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997, 95:1363-1365.
19. Kitakaze M., Minamino T., Node K., et al. Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure. Cardiovasc Drugs Ther 1998, 12:307-309.
20. Wagner D.R., Combes A., McTiernan C., Sanders V.J., Lemster B., Feldman A.M. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha. Circ Res 1998, 82:47-56.
21. Ke J.J., Yu F.X., Rao Y., Wang Y.L. Adenosine postconditioning protects against myocardial ischemia-reperfusion injury though modulate production of TNF-alpha and prevents activation of transcription factor NF-kappaB. Mol Biol Rep 2011, 38:531-538.
22. Xu X., Fassett J., Hu X., et al. Ecto-5'-nucleotidase deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction. Hypertension 2008, 51:1557-1564.
23. Liao Y., Takashima S., Asano Y., et al. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 2003, 93:759-766.
24. Zhao H., Liao Y., Minamino T., et al. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res 2008, 31:1977-1987.
25. Simpson P., McGrath A., Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 1982, 51:787-801.
26. Asakura M., Kitakaze M., Takashima S., et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002, 8:35-40.
27. Yamane R., Nakamura T., Matsuura E., Ishige H., Fujimoto M. A simple and sensitive radioimmunoassay for adenosine. J Immunoassay 1991, 12:501-519.
28. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
29. Monden Y., Kubota T., Inoue T., et al. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. Am J Physiol Heart Circ Physiol 2007, 293:H743-H753.
30. Fassett J.T., Xu X., Hu X., et al. Adenosine regulation of microtubule dynamics in cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2009, 297:H523-H532.
31. Hill J.A., Karimi M., Kutschke W., et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 2000, 101:2863-2869.
32. Esposito G., Rapacciuolo A., Naga Prasad S.V., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002, 105:85-92.